MAPT and Alzheimer disease: Findings from Fortea et al. [21] revealed that nearly all APOE4 homozygotes presented with AD pathology and increased concentrations of both CSF (Aβ1–42 and p-tau) and plasma biomarkers (p-tau and NfL), supporting the use of APOE4 as a proxy for AD pathophysiology.